Derm
Erythema Multiforme
search
Erythema Multiforme
, Erythema Multiforme Minor
See Also
Erythema Multiforme Major
(
Stevens Johnson Syndrome
)
Toxic Epidermal Necrolysis
Epidemiology
Age: Peaks age 20-40 (20% of cases under age 18)
Gender: Males affected more often than females
Pathophysiology
Type IV
Hypersensitivity Reaction
(T
Lymphocyte
mediated) to various
Antigen
s
Self limited mucocutaneous reaction
Reaction to
Antigen
deposition within the skin
Triggers cell-mediated
Immunity
Types
Erythema Multiforme Minor
Now known simply as Erythema Multiforme
Other forms below are distinct entities
Erythema Multiforme Major
(
Stevens Johnson Syndrome
)
Previously thought to be along same spectrum as minor
Now thought to be distinct entity, with mucous membrane involvement
May include
Toxic Epidermal Necrolysis
Causes
See
Erythema Multiforme Causes
Infections (90% of cases)
Herpes Simplex Virus
and
Mycoplasma pneumoniae
are most common
Medications (10% of cases)
Symptoms
Lesion onset typically 3 to 5 days after initial exposure
Onset up to 1 to 3 weeks after medication exposure
Mild prodrome for 7-10 days may be present (more common with mucosal lesions,
Erythema Multiforme Major
)
Malaise
Fever
Headache
Rhinorrhea
Cough
Rash
Develops 3-5 days after prodrome
Lesions persist up to 1 to 2 weeks
Rash may burn or itch
Signs
Distinctive Target or
Iris
skin lesion
Starts as a dull erythematous (pink or red)
Macule
that becomes raised
Centripetal spread (extremities to trunk) into target lesion over 3-5 days (often by day 2)
Center: Dusky erythema or
Vesicle
Middle: Pale edematous ring
Outer: Dark band of erythema
Distribution: Symmetrical involvement with centripetal spread
Onset on distal extremities (often dorsal hands, as well as palms and soles)
Progress proximally (often extensor surfaces)
However, trunk is typically affected less than extremities
Predilection for current areas of
Trauma
or
Sunburn
Features absent in Erythema Multiforme Minor (contrast with EM Major and TEN)
Oral Mucosa
l involvement is absent in Erythema Multiforme Minor
Nikolsky Sign
is absent in Erythema Multiforme Minor
Non-toxic patient appearance
Progresses
Central necrosis
Some lesions may coalesce into annular
Plaque
s
Healing
Most lesions heal without complication
Scarring or
Postinflammatory Hyperpigmentation
may occur
Alternative presentations
Non-transient
Urticaria
l
Plaque
s
Vesicle
s or bullae form in prior
Macule
or wheal
Labs
None are necessary (use for differential diagnosis)
Complete Blood Count
Skin Biopsy (if diagnosis unclear)
Biopsy with direct immunofluorescence distinguishes
Bullous Disease
s
Consider evaluating for underlying etiology
Herpes Simplex Virus
Tzanck Preparation
of skin lesion
Mycoplasma pneumoniae
Complement fixation
Cold
Agglutinin
s
Chest XRay
Differential Diagnosis
See
Erythema Multiforme Differential Diagnosis
Erythema Multiforme Major
Associated with mucosal lesions (distinguishes from
Erythema Multiforme Major
)
Mucosal lesions (esp mouth) are seen in 25-60% of Erythema Multiforme cases
Management
Acute Erythema Multiforme Minor
Elimination of precipitating factors
Herpes Simplex Virus
Mycoplasma pneumoniae
Suspected drug or food item
Mild Involvement: Supportive care
Analgesic
s
Oral
Antihistamine
s
Skin lesions
Wet Dressings
or soaks
Topical Corticosteroid
s (questionable efficacy)
Moderate Erythema Multiforme Minor
Oral
Acyclovir
Prednisone
(controversial, not typically recommended)
Dose: 40-80 mg PO daily for 1-2 weeks, then taper
Oral Lesion
s (
Erythema Multiforme Major
)
See
Erythema Multiforme Major
Saline mouth rinses
Home Precautions
Return for fever, new systemic symptoms, large bullae or
Oral Lesion
s
Management
Recurent Erythema Multiforme Minor
Background
In some patients, may recur multiple times in one year (mean 6 episodes/year over 6-10 years)
Conditions associated with recurrent
Erythema Migrans
(idiopathic in 60% of cases)
Herpes Simplex Virus
(thought to be related to many recurrence episodes, even without outbreak)
Mycoplasma pneumoniae
Hepatitis C
Menstruation
Systemic
Antiviral
s
Continue until lesion-free for 4 months
Then taper dose gradually
First-line
Acyclovir
400 mg orally twice daily
Second-line if
Acyclovir
ineffective
Valacyclovir
500 mg orally twice daily
Famciclovir
250 mg orally twice daily
References
Tatnail (1995) Br J Dermatol 132(2): 267-70 [PubMed]
Other agents in refractory cases
Prescribed by Dermatology
Agents (high rate of adverse effects)
Dapsone
Hydroxychloroquine
Azathoprine
Cyclosporine
Thalidomide
Course
New lesions occur over 3-5 days
Lesions persist for 1-2 weeks (non-migratory)
Contrast with
Urticaria
that last <24 hours
Resolves spontaneously in 3-5 weeks
HSV related lesions typically resolve by 2 weeks
Recurrence
See above
References
Long (2016) Crit Dec Emerg Med 30(7):3-10
Sanelich (2024) Crit Dec Emerg Med 38(3): 16-17
Lamoreux (2006) Am Fam Physician 74:1883-8 [PubMed]
Leaute-Labreze (2000) Arch Dis Child 83:347-52 [PubMed]
Trayes (2019) Am Fam Physician 100(2): 82-8 [PubMed]
Williams (2005) Dent Clin North Am 49:67-76 [PubMed]
Type your search phrase here